Evidence map›Paper›PMID 42548496›Full record

ArticleFrontiers in immunology2026

MICA-129Met/Val as a therapeutic compass in idiopathic pulmonary fibrosis: prognosis and antifibrotic benefit.

Stefano Mocci, Caterina Mereu, Roberto Littera, Silvia Deidda, Federica Cannas, Michela Lorrai, Elena Zedda, Michela Murgia, Celeste Sanna, Erika Giuressi and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Stefano Mocci *Medical Genetics, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Caterina Mereu *Medical Genetics, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Roberto LitteraMedical Genetics, R. Binaghi Hospital, Cagliari, Italy.
Silvia DeiddaPneumology Unit, R. Binaghi Hospital, Cagliari, Italy.
Federica CannasMedical Genetics, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Michela LorraiMedical Genetics, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Elena ZeddaMedical Genetics, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Michela MurgiaMedical Genetics, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Celeste SannaMedical Genetics, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Erika GiuressiMedical Genetics, R. Binaghi Hospital, Cagliari, Italy.
Sara LaiMedical Genetics, R. Binaghi Hospital, Cagliari, Italy.
Andrea PerraAART-ODV (Association for the Advancement of Research on Transplantation), Cagliari, Italy.
Matteo FlorisDepartment of Biomedical Sciences, University of Sassari, Sassari, Sardinia, Italy.
Sabrina GiglioMedical Genetics, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease characterized by aberrant wound healing, immune dysregulation, heterogeneous trajectories, and poor prognosis. Only two antifibrotic agents, Methods: We analyzed clinical and genetic data from 129 Sardinian IPF patients genotyped for MICA and stratified by antifibrotic therapy ( Results: Conclusions: The

Indexed as

Antifibrotic AgentsHistocompatibility Antigens Class IIdiopathic Pulmonary FibrosisAgedFemaleGenotypeHumansIndolesKiller Cells, NaturalMaleMiddle AgedPrognosisPyridonesTreatment OutcomeAntifibrotic AgentsHistocompatibility Antigens Class IIndolesMHC class I-related chain AnintedanibpirfenidonePyridonesantifibrotic therapyidiopathic pulmonary fibrosisMet129ValMICAnintedanib

Identifiers

PMID42548496
PMCPMC13429406

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.